Locust Walk examined how regional licensing trends are evolving and potential deal strategies to navigate uncertainty amid three converging regulatory shifts: the U.S. Most‑Favored Nation (MFN) Executive Order and proposed GLOBE/GUARD rules, the EU Pharmaceutical Package, and Japan’s NHI pricing reform.
Locust Walk examined the evolving landscape of cross-border transactions involving Chinese biotech and what it truly takes to succeed as a global dealmaker in today’s market.
Podcast: Play in new window | Download (Duration: 7:35 — 6.9MB)
Subscribe: Apple Podcasts | Spotify | RSS
During the Asia-focused Episode 35 of Biotalk, Geoff Meyerson, CEO of Locust Walk, reviews key 2026 Q1 Report: Global Trends in Biopharma Transactions trends across China,
Podcast: Play in new window | Download (Duration: 5:12 — 9.5MB)
Subscribe: Apple Podcasts | Spotify | RSS
During Episode 34 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2026 Q1 Report: Global Trends in Biopharma Transactions, covering capital markets, strategic deals, and
LOCUST WALK NEWS Banyan BioInnovations Launches as an Investment Firm to Support Clinical-Stage Drug Assets, Secures More Than $100M Initial
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2026 Q1 Report applies the latest data to analyze the current landscape in life sciences deals.
Podcast: Play in new window | Download (Duration: 6:08 — 14.0MB)
Subscribe: Apple Podcasts | Spotify | RSS
During the Asia-focused Episode 33 of Biotalk, Geoff Meyerson, CEO of Locust Walk, reviews key 2025 Year-In-Review trends across China, Japan, and
Podcast: Play in new window | Download (Duration: 11:24 — 26.1MB)
Subscribe: Apple Podcasts | Spotify | RSS
During Episode 32 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Year-In-Review Report: Global Trends in Biopharma
Locust Walk conducted a multi‑year analysis of JPM‑week deal activity to evaluate whether early‑January partnering and M&A activity can reliably benchmark and anticipate full‑year dealmaking momentum across global biopharma.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2025 Year-In-Review Report applies the latest data to analyze the current landscape in life sciences deals.